港股异动|歌礼制药涨5.45%治疗丙型肝炎的复方制剂临床试验申请获药监局批准
格隆汇8月16日丨歌礼制药-B(01672.HK)涨5.45%,报4.06港元,成交205万港元,总市值45.5亿港元。歌礼制药-B(01672.HK)上周公布,公司ASC18临床试验申请获得国家药品监督管理局批准。ASC18是用于治疗丙型肝炎的每日口服一次、每次一片的固定剂量复方制剂(FDC)。公告称,管理团队有信心实现公司2019年的目标,包括医保准入、研发,以及引进、收购处于临床阶段和已商业化的项目,同时进一步提升公司财务业绩表现。管理团队也对公司2020年及今后的发展前景持乐观态度。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.